Invex Net Receivables from 2010 to 2024
| IXC Stock | 0.07 0.01 7.46% |
Net Receivables | First Reported 2010-12-31 | Previous Quarter 95 K | Current Value 146.3 K | Quarterly Volatility 68.7 K |
Check Invex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Invex Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 3.8 M or Interest Expense of 96.5 K, as well as many indicators such as . Invex financial statements analysis is a perfect complement when working with Invex Therapeutics Valuation or Volatility modules.
Invex | Net Receivables |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Invex Stock Analysis
When running Invex Therapeutics' price analysis, check to measure Invex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Invex Therapeutics is operating at the current time. Most of Invex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Invex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Invex Therapeutics' price. Additionally, you may evaluate how the addition of Invex Therapeutics to your portfolios can decrease your overall portfolio volatility.